Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSPORT: Lumacaftor/Ivacaftor in CF F508del Homozygous
NCT01807949Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of lumacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second at 24 weeks. Started Apr 2013; status: completed.
02
Drugs
lumacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01807949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01807949.